Research programme: CNS therapeutics - Denali/Blaze Bioscience/Fred Hutchinson Cancer Research Center

Drug Profile

Research programme: CNS therapeutics - Denali/Blaze Bioscience/Fred Hutchinson Cancer Research Center

Latest Information Update: 30 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Blaze Bioscience; Fred Hutchinson Cancer Research Center
  • Developer Blaze Bioscience; Denali Therapeutics Inc; Fred Hutchinson Cancer Research Center
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research CNS disorders

Most Recent Events

  • 25 Aug 2016 Denali Therapeutics, Fred Hutchinson Cancer Research Center and Blaze Bioscience agree to co-develop CNS therapeutics
  • 25 Aug 2016 Early research in CNS disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top